8 completed. 8 Phase 3.
By phase and status
Follow Neurodermatitis: new trials by email Literature Review of Neurodermatitis trials Research Report on Neurodermatitis
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
Dupilumab, Placebo - Lichen Simplex Chronicus | Phase 3 | Completed | 142 | 2024-11-28 | 2026-09-11 |
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
Dupilumab, Placebo - Lichen Simplex Chronicus | Phase 3 | Completed | 138 | 2024-11-25 | 2026-09-11 |
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Nemolizumab 30 mg, Placebo - Prurigo Nodularis | Phase 3 | Completed | 286 | 2020-09-11 | 2024-07-10 |
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Nemolizumab, Placebo - Prurigo Nodularis | Phase 3 | Completed | 274 | 2020-08-11 | 2024-07-10 |
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Dupilumab SAR231893, Placebo, Moisturizers - Neurodermatitis | Phase 3 | Completed | 160 | 2020-01-16 | 2025-09-17 |
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Dupilumab SAR231893, Placebo, Moisturizers - Neurodermatitis | Phase 3 | Completed | 151 | 2019-12-12 | 2025-09-17 |
Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
Selegiline, Placebo (for Selegiline) - Borderline Personality Disorder | Phase 3 | Completed | 30 | 2012-10-01 | 2015-10-08 |
Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis
silver-contained textiles, corticosteroid - Neurodermatitis | Phase 3 | Completed | 32 | 2004-01-01 | 2005-09-20 |
Narrower conditions
Prurigo (2) · Pruritus (2) · Skin Diseases (2) · Anxiety Disorders (1) · Borderline Personality Disorder (1) · Depression (1) · Fibromyalgia (1) · Headache (1) · Irritable Bowel Syndrome (1) · Migraine Disorders (1) · Premenstrual Syndrome (1)
Broader conditions
Dermatitis (8) · Skin Diseases, Eczematous (8) · Skin and Connective Tissue Diseases (8) · Skin Diseases (6) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Skin Manifestations (2) · Behavior (1) · Behavioral Symptoms (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Colonic Diseases (1) · Colonic Diseases, Functional (1) · Digestive System Diseases (1) · Gastrointestinal Diseases (1)
Interventions
dupilumab (4) · Calcineurin Inhibitors (2) · nemolizumab (2) · Adrenal Cortex Hormones (1) · Selegiline (1)
Sponsors
Sanofi (4) · Galderma R&D (2) · Mood and Anxiety Research, Inc (1) · University Medicine Greifswald (1)
Countries
United States (7) · Canada (5) · Germany (4) · Hungary (4) · Italy (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Argentina (3) · Chile (3) · China (3) · France (3) · Mexico (3) · Taiwan (3) · Belgium (2)
Top investigators
Andrea Ladwig (1) · Paul J Markovitz, MD, PhD (1)
Results publications
PMID 37142763, PMID 37888917, PMID 38865146, PMID 40266487, PMID 41219577, PMID 41922877, PMID 42120670, PMID 36375174, PMID 39602139, PMID 41272364
NIH funding
2019 (4)